Strong association of C-reactive protein with body mass index and 2-h post-challege glucose in non-diabetic, non-smoker subjects without hypertension

Diabetic Medicine

Volumn 21, Issue 6, 2004, Pages 581-585

  Hashimoto, K ^a   Kasayama, S ^b,c   Yamamoto, H ^b   Kurebayashi, S ^a,b   Kawase, I ^b   Koga, M ^a  

^a Kinki Central Hospital of Mutual Association of Public School Teachers   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Body mass index; Cardiovascular risk factors; Inflammation; Oral glucose tolerance test; Post challenge glucose

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIABETIC HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INFLAMMATION; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXAMINATION; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LIPASE; MALE; MIDDLE AGED; RISK FACTORS; URIC ACID;

EID: 2942578929     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01212.x     Document Type: Article

References (39)

1. Panzram G, Zabel-Langhennig R. Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 1981; 20: 587-591.
2. Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987; 3: 463-524.
3. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 1999; 48: 937-942.
4. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
5. Balkau B, Shipley M, Jarrett RJ, Pyörälä K, Pyörälä M, Forhan A et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 1998; 21: 360-366.
6. The DECODE Study Group on behalf of the European Diabetes Etiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-621.
7. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willen WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134.
8. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care 1999; 22: 920-924.
9. 1c level. Diabetes Care 2000; 23: 1830-1834.
10. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999; 340: 115-126.
11. Mendall MA, Patel P, Ballan L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-1065.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Eng J Med 1997; 336: 973-979.
13. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 2000; 342: 836-843.
14. Harris T, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr. et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512.
15. Otsuki M, Hashimoto K, Morimoto Y, Kishimoto T, Kasayama S. Circulating vascular cell adhesion molecule-1 (VCAM-1) in atherosclerotic NIDDM patients. Diabetes 1997; 46: 2096-2101.
16. Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18: 1765-1770.
17. Maresca G, Di Blasio A, Marchidi R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.
18. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-2579.
19. Wang TJ, Nam B, Wilson PWF, Wolf PA, Levy D, Polak JF et al. Association of C-reactive protein with carotid atherosclerosis in men and women: The Framingham Heart Study. Arterioscler Thromb Vasc Biol 2002; 22: 1662-1667.
20. Bloemenkamp DGM, van den Bosch MAAJ, Mali WPTM, Tanis BC, Rosendaal FR, Kemmeren JM et al. Novel risk factors for peripheral arterial disease in young women. Am J Med 2002; 113: 462-467.
21. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 2000; 102: 42-47.
22. Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationship among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-1673.
23. Church TS, Barlow CE, Earnest CP, Kampert JB, Priest EL, Bair SN. Association between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol 2002; 22: 1869-1876.
24. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary heart disease in the atherosclerosis risk in communities (ARIC) study. Am Heart J 2002; 144: 233-238.
25. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
26. Temelkova-Kurktschiev T, Henkel E, Koehler C, Karrei K, Hanefeld M. Subdinical inflammation in newly detected type II diabetes and impaired glucose tolerance. Diabetologia 2002; 45: 151.
27. Schalkwijik CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351-357.
28. Tan KCB, Chow WS, Tam SCF, Ai VHG, Lam CHL, Lam KSL. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-568.
29. Unwin N, Shaw J, Zimmet P, Alberti KGMM. Impaired glucose tolerance and impaired fasting glycemia, the current status on definition and intervention. Diabet Med 2002; 19: 708-723.
30. Alberti KGMM, Zimmet PZ for the WHO Consultation. Definition, diagnosis and classification of diabetes, mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
31. Friedwald WT, Levy RI, Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
32. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. C-reactive protein is more strongly related to post-glucose load glucose than to fasting glucose in non-diabetic subjects. The Insulin Resistance Atherosclerosis Study. Diabet Med 2002; 19: 939-943.
33. Temelkova-Kurktschiev T, Siegert G, Bergmann S, Henkel E, Koehler C, Jaross W et al. Subclinical inflammation is strongly related to insulin resistance but not impaired insulin secretion in a high risk population for diabetes. Metabolism 2002; 51: 743-749.
34. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women. J Intern Med 2001; 250: 502-507.
35. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149: 1514-1520.
36. Coppack SW. Proinflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-356.
37. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effects of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
38. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919.
39. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.